摘要 |
The invention is directed to a method of treating a mammal afflicted with a retroviral-associated neurological disease through the administration of an effective amount of a bystander antigen. The bystander antigen is selected such that it elicits the release of transforming growth factor beta (TGF-(beta)) from suppressor T-cells, and, preferably, targets the T-cells to the loci in the body (i.e., the neural tissue) of the mammal which is under cytotoxic attack during the neurological disease. The released TGF-(beta) suppresses the cells responsible for the cytotoxic attack, thus reducing the neurological disease. |